Los Angeles Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
Other funds holding RETA
CI
Los Angeles Capital Management's RETA Position: Q4 2021 in Review
Los Angeles Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2021, closing a stake of 2,257 shares — an estimated $227K sold.
Los Angeles Capital Management first reported a position in RETA in Q1 2021 and held it in 2 quarters. The position peaked at $244K in Q1 2021. 151 funds tracked by Wall St. Rank hold RETA as of Q4 2021.
- Los Angeles Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2021 after selling out during the quarter.
- Los Angeles Capital Management sold 2,257 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2021, an estimated $227K.
- Los Angeles Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2021 and held it in 2 quarters.
- Los Angeles Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $244K in Q1 2021.
- 151 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2021.
Based on Los Angeles Capital Management's 13F filing for Q4 2021, filed 3 Feb 2022.